Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To compare the efficacy, tolerability and safety of alemtuzumab versus interferon beta 1a in the treatment of patients with relapsing-remitting multiple sclerosis to prevent disease activity.